Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (December 2023)
42 slides from Genetic Signatures's investor presentation, Dec 21, 2023
Slide 1: Not for release to US wire services or distribution in the United States
Not for release to US wire services or distribution in the United States
Slide 2: Disclaimer
Capital raising presentation Disclaimer 21 December 2023 2
Slide 3: Capital raising presentation
Capital raising presentation 21 December 2023 • Proprietary 3base® technology • underpinning an automated • diagnostic workflow • • Molecular diagnostic (MDx) • market estimated at ~A$35b • with growing syndromic testing segment expected to reach A$4.3b by 2026 • • ™ First product to be launched in
Slide 4: Capital raising presentation
Capital raising presentation 21 December 2023 • Next Generation Instrument • development to drive future growth • • • ™ Significant news flow and • ™ catalysts expected in the near term • • • Seeking to raise $15.9m to • support future growth • 4
Slide 5: Capital raising presentation
Capital raising presentation 21 December 2023 • • • • • • • • 5
Slide 6: Capital raising presentation
Capital raising presentation 21 December 2023 • • • • 6
Slide 7: Capital raising presentation
Capital raising presentation 21 December 2023 • • • • • 7
Slide 8: US team representation at ASM Microbe 2023 conference in Houston, Texas
Capital raising presentation 21 December 2023 US team representation at ASM Microbe 2023 conference in Houston, Texas. 8
Slide 9: Target segments GI parasite testing
Capital raising presentation 21 December 2023 *EP005 = EasyScreenTM Gastrointestinal Parasite Detection Kit Target GI parasite testing Potential TAM Share of targeted 2.2m Potential customers segments requirements = 5.5 m tests EP005* tests by segment • LabCorp High volume • Quest Large commercial 1
Slide 10: Capital raising presentation
Capital raising presentation 21 December 2023 • • • • 10
Slide 11: Capital expenditure on research & development & the Next Generation Instrument
Capital raising presentation 21 December 2023 • • • • • • Capital expenditure on research & development (R&D) & the Next Generation Instrument (FY - $A million) 9.1* 4.0 R&D Next Generation Instrument 4.1 1.0 5.1 2.8 3.1 1.8 1.2 FY2019 FY2020 FY2021 FY2022 FY2023 11 11
Slide 12: Capital raising presentation
Capital raising presentation 21 December 2023 • • • • • • • • Design development • Performance testing • Research • Manufacturing • Sample to answer build • User feedback • FDA/IVDR submission • OEM review partnership • Consumable build • Informatics • Regulatory clearance • Form design • Support tr
Slide 13: Capital raising presentation
Capital raising presentation 21 December 2023 • • • • • • 13
Slide 14: Cost reduction initiatives
Capital raising presentation 21 December 2023 Cost reduction initiatives Head count reductions and recruitment moratorium Reduction in R&D and clinical trial expenditure through deferral of less critical programs Deferral of Next Generation Instrument development Total • • • 14
Slide 15: Capital raising presentation
Capital raising presentation 21 December 2023 15
Slide 16: Board and management
Capital raising presentation 21 December 2023 Nick Samaras Michael Aicher John Melki Non Executive Chairman Executive Director Managing Director and CEO • Significant experience leading • Currently based in the US with • Led global commercialisation efforts international sales teams significant expe
Slide 17: Capital raising presentation
Capital raising presentation 21 December 2023 • • • • • • • • • 17 17
Slide 18: Offer Details
§ senetic Signatures Offer Details
Slide 19: Offer Structure
Capital raising presentation 21 December 2023 ▪ ▪ Offer Structure ▪ ▪ ▪ Offer Price ▪ ▪ ▪ ▪ Entitlement Offer ▪ Record Date ▪ ▪ Ranking ▪ Joint Lead Managers ▪ and Underwriters 19
Slide 20: Use of funds
Capital raising presentation 21 December 2023 • Additional regulatory approvals ‒ • Funding for new customer installations • • Next Generation Instrument development and new product • development • 20
Slide 21: Capital raising presentation
Capital raising presentation 21 December 2023 21
Slide 22: Appendix
\sforming Molecular Diagnosti § senetic Signatures Appendix
Slide 23: Capital raising presentation
Capital raising presentation 21 December 2023 • • • • • • 23
Slide 24: C→T most common mutation
Capital raising presentation 21 December 2023 C→T most common mutation * Human Papilloma virus sequences 24
Slide 25: Capital raising presentation
Capital raising presentation 21 December 2023 • • • • • • 25
Slide 26: Robust pipeline with multiple products cleared for sale
Capital raising presentation Robust pipeline with multiple products cleared for sale 21 December 2023 DEVELOPMENT RESEARCH USE REGISTRATION TGA CE Mark FDA In clinical trials Submitted Converting to new protocol In development 26
Slide 27: Revenue $m
Capital raising presentation 21 December 2023 • • • • 40 Pandemic 35 3.8 30 Revenue $m 25 6.0 20 15 31.6 1.6 22.2 10 1.1 15.4 10.2 5 4.9 0 FY2019 FY2020 FY2021 FY2022 FY2023 APAC Rest of world 27 NOTE: EasyScreen™ SARS-CoV-2 Detection Kit sales commenced during FY2020
Slide 28: Syndromic vs COVID-only revenue
Capital raising presentation 21 December 2023 • • • • • Pandemic 40 35 30 25 26.4 20 16.4 15 4.3 10 1.7 5 11.8 12.6 9.6 9.1 4.9 0 FY2019 FY2020 FY2021 FY2022 FY2023 Syndromic COVID-only 28
Slide 29: US Medicare Part B Allowed Test Volumes
Capital raising presentation 21 December 2023 US PCR-based (excluding COVID) Medicare Part B carrier allowed claims 15 No. of tests (millions) 10 11.4 12.6 13.8 5 6.1 0 2019 2020 2021 2022 US Medicare Part B Allowed Test Volumes SOURCE: Laboratory Economics, Vol 18, No. 11, 11 November 2023 29
Slide 30: Key Risks
Capital raising presentation 21 December 2023 1. KEY RISKS Investors should be aware that an investment in Genetic Signatures involves risks. The key risks identified by Genetic Signatures are set out in the "Key Risks" section of the Investor Presentation (below), but these are not an exhaustive li
Slide 31: Country/region specific risks in new and/or unfamiliar markets
Capital raising presentation 21 December 2023 COUNTRY/REGION SPECIFIC RISKS IN NEW AND/OR UNFAMILIAR MARKETS Genetic Signatures has operations in a number of overseas jurisdictions and is exposed to a range of different legal and regulatory regimes, including in new jurisdictions in which Genetic Si
Slide 32: Loss of adoption by customers
Capital raising presentation 21 December 2023 LOSS OF ADOPTION BY CUSTOMERS Genetic Signatures is reliant on pathology laboratories purchasing its products. Healthcare practitioners play a significant role in influencing the types of tests and products used by patients. To achieve commercial success
Slide 33: General regulatory risks
Capital raising presentation 21 December 2023 GENERAL REGULATORY RISKS The Company operates and intends to operate in regulated industries (including but not limited to medical devices, diagnostics and therapeutics) in Australia and internationally. Given Genetic Signatures’ international expansion
Slide 34: Changes to accounting policies and/or methods
Capital raising presentation 21 December 2023 CHANGES TO ACCOUNTING POLICIES AND/OR METHODS IN WHICH THEY ARE APPLIED MAY ADVERSELY AFFECT GENETIC SIGNATURES’ BUSINESS, OPERATIONS AND FINANCIAL CONDITION The accounting policies and methods that Genetic Signatures applies are fundamental to how it re
Slide 35: Offer and general risks
Capital raising presentation 21 December 2023 2. OFFER AND GENERAL RISKS MARKET PRICE OF ORDINARY SHARES WILL FLUCTUATE Ordinary shares trade on ASX. The market price of ordinary shares on ASX may fluctuate due to various factors, including: • the impact of COVID-19, or other pandemics or epidemics,
Slide 36: Liquidity risk
Capital raising presentation 21 December 2023 LIQUIDITY RISK Genetic Signatures Shareholders who wish to sell their ordinary shares may be unable to do so at an acceptable price, or at all, if insufficient liquidity exists in the market for ordinary shares. Genetic Signatures does not guarantee the
Slide 37: International Offer Restrictions
Capital raising presentation 21 December 2023 International Offer Restrictions This Presentation does not constitute an offer of new ordinary shares (“New Shares”) of the Company in any jurisdiction in which it would be unlawful. In particular, this Presentation may not be distributed to any person,
Slide 38: Singapore
Capital raising presentation 21 December 2023 Singapore This Presentation and any other materials relating to the New Shares have not been, and will not be, lodged or registered as a prospectus in Singapore with the Monetary Authority of Singapore. Accordingly, this Presentation and any other docume
Slide 39: Key terms of the Underwriting Agreement
Capital raising presentation 21 December 2023 The Company has entered into an underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited ACN 006 390 772 and Taylor Collison Limited ACN 008 172 450 (each an Underwriter, and together the Underwriters) pursuant to which the Und
Slide 40: Key terms of the Underwriting Agreement (continued)
Capital raising presentation 21 December 2023 Key terms of the Underwriting Agreement (continued) • a transaction is announced (including without limitation a scheme of arrangement, reconstruction or takeover bid under the Corporations Act), whether by the Company or by another person, which, if imp
Slide 41: Key terms of the Underwriting Agreement (continued)
Capital raising presentation 21 December 2023 Key terms of the Underwriting Agreement (continued) • a change in certain senior management of the Company or in the board of directors of the Company is announced or occurs without the Underwriters' prior written consent; • in the reasonable opinion of
Slide 42: Contact Us
Contact Us Dr John Melki Managing Director & Chief Executive Officer E: john.melki@geneticsignatures.com P: +61 (0)2 9870 7580 Karl Pechmann Chief Financial & Operating Officer & Company Secretary E: karl.pechmann@geneticsignatures.com Visit us www.geneticsignatures.com Follow us 42
Genetic Signatures — Investor Presentation (December 2023) on 6ix